Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) Latest Company News

Oct 27, 2026, 08:09 UTC
China's National Medical Products Administration approved Anhui Zhifei Longcom Biopharmaceutical Co.'s freeze-dried human rabies vaccine, with approval number S20260079.
Source:
- finance.sina.cn
Oct 26, 2026, 10:20 UTC
Zhifei Biological Products reported third-quarter revenue of 2.515 billion yuan, down 7.40% year over year, and net profit of 125 million yuan, up 117.36%; first-three-quarter revenue was 6.539 billion yuan, down 14.46%, and net loss was 683 million yuan.
Source:
- finance.sina.cn
Oct 26, 2026, 09:57 UTC
Chongqing Branch of Bank of China issued Zhifei Biological Products a commitment for a dedicated share-repurchase loan of up to RMB 210 million, capped at 70% of the repurchase transaction price and with a term of up to three years.
Source:
- finance.sina.cn
Oct 23, 2026, 08:01 UTC
China's National Medical Products Administration approved clinical trials for Zhifei Lvzhu's intranasal recombinant respiratory syncytial virus vaccine, allowing trials to assess prevention of related diseases.
Source:
- finance.sina.cn
Sep 30, 2026, 09:47 UTC
On the last trading day before China's National Day holiday, Chinese pharmaceutical stocks surged broadly, with the pharma index closing up 2.73% and the innovative drug index up 3.42%, while semiconductors fell 2.75%.
Source:
- finance.ifeng.com
Sep 23, 2026, 09:12 UTC
Chongqing Zhifei Biological Products said it is advancing its internationalization strategy, including exports of its quadrivalent meningococcal polysaccharide vaccine and overseas clinical work for its bivalent Shigella flexneri-Sonnei conjugate vaccine and 26-valent pneumococcal conjugate vaccine.
Source:
- finance.sina.cn
Sep 23, 2026, 09:12 UTC
Chongqing Zhifei Biological Products disclosed at the Chongqing listed-company investor reception that it has 15 products on sale, including vaccines, tuberculosis biologics and metabolic-disease drugs, and 42 self-developed pipeline projects.
Source:
- finance.sina.cn
Sep 22, 2026, 19:15 UTC
More than 40 vaccine manufacturers from 17 developing countries, including nine from China, gathered in Beijing for the 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN), co-hosted by DCVMN with BJFPI, Sinovac, BioKangtai and Zhifei.
Source:
- finanznachrichten.de
- intelligencer.ca
Sep 11, 2026, 06:37 UTC
Chongqing Chenan Biopharmaceutical, a controlled subsidiary of Zhifei Biological, launched its self-developed liraglutide injection (brand name Dashuchen) into clinical use, with the first nationwide injection administered at Banan Hospital Affiliated to Chongqing Medical University.
Source:
- finance.sina.cn
Sep 8, 2026, 08:57 UTC
Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical received acceptance notices from China's National Medical Products Administration for its production registration applications for semaglutide injection, a self-developed biosimilar for type 2 diabetes.
Source:
- finance.sina.cn
Sep 7, 2026, 08:38 UTC
Zhifei Biological's wholly-owned subsidiary Beijing Zhifei Luzhu Biopharmaceutical received clinical trial approval from China's National Medical Products Administration for its recombinant rotavirus subunit vaccine to prevent acute gastroenteritis in infants and children.
Source:
- finance.sina.cn
Sep 4, 2026, 07:54 UTC
Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.
Source:
- finance.sina.cn
Sep 1, 2026, 08:53 UTC
Zhifei Biological's subsidiary Anhui Zhifei Longcom Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of a freeze-dried human rabies vaccine (ZFB-3 cells), allowing trials to proceed within 60 days if no objections are raised.
Source:
- finance.sina.cn
Aug 28, 2026, 11:11 UTC
Zhifei Biological reported a net loss of 809 million yuan for the first half of 2026, compared with a loss of 606 million yuan in the same period of 2025.
Source:
- finance.sina.cn
Aug 13, 2026, 01:57 UTC
Zhifei Biological's controlled subsidiary Chen'an Bio completed first-subject enrollment in the Phase Ib clinical trial of its CA111 injection on August 12, 2026.
Source:
- finance.sina.cn
Aug 10, 2026, 10:31 UTC
Zhifei Biological's wholly-owned subsidiary Zhifei Luzhu's clinical trial application for a nasal spray recombinant respiratory syncytial virus vaccine was accepted by the National Medical Products Administration, with acceptance number CXSL2600844.
Source:
- finance.sina.cn
Jul 20, 2026, 10:39 UTC
Zhifei Biological plans to repurchase its own shares for 150 million to 300 million yuan at a price not exceeding 18.22 yuan per share.
Source:
- finance.sina.cn
Jul 10, 2026, 10:30 UTC
Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. received a Drug Registration Certificate from the National Medical Products Administration for its liraglutide injection.
Source:
- finance.sina.cn

300122.SZ

China's National Medical Products Administration approved Anhui Zhifei Longcom Biopharmaceutical Co.'s freeze-dried human rabies vaccine, with approval number S20260079.

Zhifei Biological Products reported third-quarter revenue of 2.515 billion yuan, down 7.40% year over year, and net profit of 125 million yuan, up 117.36%; first-three-quarter revenue was 6.539 billion yuan, down 14.46%, and net loss was 683 million yuan.

Chongqing Branch of Bank of China issued Zhifei Biological Products a commitment for a dedicated share-repurchase loan of up to RMB 210 million, capped at 70% of the repurchase transaction price and with a term of up to three years.

China's National Medical Products Administration approved clinical trials for Zhifei Lvzhu's intranasal recombinant respiratory syncytial virus vaccine, allowing trials to assess prevention of related diseases.

On the last trading day before China's National Day holiday, Chinese pharmaceutical stocks surged broadly, with the pharma index closing up 2.73% and the innovative drug index up 3.42%, while semiconductors fell 2.75%.

Chongqing Zhifei Biological Products disclosed at the Chongqing listed-company investor reception that it has 15 products on sale, including vaccines, tuberculosis biologics and metabolic-disease drugs, and 42 self-developed pipeline projects.

More than 40 vaccine manufacturers from 17 developing countries, including nine from China, gathered in Beijing for the 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN), co-hosted by DCVMN with BJFPI, Sinovac, BioKangtai and Zhifei.

Chongqing Chenan Biopharmaceutical, a controlled subsidiary of Zhifei Biological, launched its self-developed liraglutide injection (brand name Dashuchen) into clinical use, with the first nationwide injection administered at Banan Hospital Affiliated to Chongqing Medical University.

Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical received acceptance notices from China's National Medical Products Administration for its production registration applications for semaglutide injection, a self-developed biosimilar for type 2 diabetes.

Zhifei Biological's wholly-owned subsidiary Beijing Zhifei Luzhu Biopharmaceutical received clinical trial approval from China's National Medical Products Administration for its recombinant rotavirus subunit vaccine to prevent acute gastroenteritis in infants and children.

Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.

Zhifei Biological reported a net loss of 809 million yuan for the first half of 2026, compared with a loss of 606 million yuan in the same period of 2025.

Zhifei Biological's controlled subsidiary Chen'an Bio completed first-subject enrollment in the Phase Ib clinical trial of its CA111 injection on August 12, 2026.

Zhifei Biological's wholly-owned subsidiary Zhifei Luzhu's clinical trial application for a nasal spray recombinant respiratory syncytial virus vaccine was accepted by the National Medical Products Administration, with acceptance number CXSL2600844.

Zhifei Biological plans to repurchase its own shares for 150 million to 300 million yuan at a price not exceeding 18.22 yuan per share.

Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. received a Drug Registration Certificate from the National Medical Products Administration for its liraglutide injection.